Law360 interviewed Blackwell Burke P.A. partner Peter J. Goss on the potential unintended consequences of a recently enacted Maine law that allows state residents to purchase prescription drugs from online pharmacies based outside the U.S. Goss noted that consumers experiencing adverse reactions will have difficulty pursuing foreign pharmacies and drug manufacturers in U.S. Courts. The full article is available to Law360 subscribers here.
Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented major pharmaceutical, medical technology, and chemical firms in hundreds of cases. Mr. Goss, who has won several published Daubert decisions, often serves as “science counsel” in life sciences litigation. He collaborates with leading experts to present complex medical and scientific evidence, both in dispositive motions and at trial. He is a frequent commentator on scientific evidence and legal developments of interest to FDA-regulated industries.
Blackwell Burke P.A., a litigation and trial boutique in Minneapolis, Minnesota, serves as national trial and litigation counsel for numerous Fortune 500 companies. The firm is recommended by Benchmark Litigation and honored as a “Go-To Law Firm” for the Top 500 Companies by Corporate Counsel magazine. The firm has represented corporate clients in practically every jurisdiction in the country, as well as several foreign countries.